NCT05937620Recruiting
Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian Cancer
Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and Indocyanine Green (ICG) in Patients With Epithelial Ovarian Cancer in Early Stages: Pilot Study
Source: ClinicalTrials.gov · Last updated 9 Feb 2026
Brief summary (registry, in English)
Study to evaluate the diagnostic precision of ICG and 99mTc nanocolloid albumin in sentinel lymph node detection in early ovarian epithelial cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 62 (estimated)
- First submitted
- 20 Jun 2023
- Start date
- 1 Sept 2023
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Fundacion Clinic per a la Recerca Biomédica
- Diseases
- Ovarian cancer
- NCT number
- NCT05937620
What you commit to
- Study type: Interventional
- Planned participants: 62
- From 1 Sept 2023 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of previous vascular surgery (cava vein, aorta, iliac blood vessels) or radiotherapy in pelvic or para-aortic area.
- Patient not able to undergo surgery.
Other illness
- Sentinel lymph node biopsy will not be performed if intraoperative histologic study shows a benign ovarian tumor, low malignancy potential tumor or expansive mucinous histology.
Lab values
- Hypersensitivity to active principle, to sodium iodide or iodine allergy.
Age
- Patients \<18 years
Other
- Pregnancy or breastfeeding
- Epithelial ovarian tumors stage FIGO III or IV.
- Impossibility to obtain a biopsy from the tumor.
- Patients with clinic hyperthyroidism, thyroid autonomous adenomas or focal and diffused autonomous alteration of thyroid gland
Who the study is looking for
- Patients with adnexal mass diagnosed with high suspicion of malignancy that will undergo intraoperative biopsy or patients with already diagnosed epithelial cancer in early stages in a previous surgery and confirmed by pathology with complete staging indicated.
- Absence of retroperitoneal ganglionary affectation and metastatic disease evaluated by preoperative imaging techniques.
- Signing of informed consent by the patient or relative in charge.
- Women with childbearing potential must compromise to use highly effective contraceptive methods (partner vasectomized, sexual abstinence) until the end of the study (last study visit).
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Laura Burunat Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
Related publications
- Lymphadenectomy in early-stage ovarian cancer: is there still a role?Int J Gynecol Cancer · 2026 · PMID 41844493
This page is information, not medical advice. Discuss any trial with your doctor.